Protalex — Investor Presentation (January 2015)
17 slides from Protalex's investor presentation, Jan 20, 2015
Slide 1: Protalex PRTX January 2015
PRTX PROTALE January, 2015
Slide 2: Forward-Looking Statement
Protalex, Inc. Forward - Looking Statement Statements made in this presentation stating the Company ’ s beliefs, intentions, and expectations are forward - looking statements. The Company ’ s actual results could differ materially from those projected herein. Additional information is contained in t
Slide 3: Protalex, Inc. (Ticker: PRTX)
Protalex, Inc. Protalex, Inc. (Ticker: PRTX) ▪ Rheumatoid Arthritis (>$18B) ▪ ITP (~$1B) ▪ Other Autoimmune Diseases ($Bs) 3 ▪ Experienced Management ▪ Strong Scientific Advisors ▪ Low - burn Model ▪ Funded - to - date by majority shareholder ▪ Highly - purified b acterial protein ▪ W ell - studied
Slide 4: The Big Picture: A Huge Market with Unmet Needs
Protalex, Inc. The BIG PICTURE A Huge Market with unmet needs o Today in the US, millions of individuals suffer from autoimmune diseases, like rheumatoid arthritis (RA) — the largest autoimmune market, and Immune Thrombocytopenia (ITP) — bruising and bleeding that does not easily heal. ITP is an orp
Slide 5: The Most Important Unmet Need is Safety
The M ost I mportant Unmet Need is SAFETY o Humira, Enbrel and Remicade are TNF - inhibitors o All three drugs suppress the immune system, and that has a major impact on those who take them. o The FDA requires them to carry a Black Box Warning for such problems as: o Congestive Heart Failure, Blood
Slide 6: FDA Black Box Warnings: A Safer RA Drug is Needed
Protalex, Inc. FDA Black Box Warnings A Safer RA drug is needed o Each major RA drug has over 12 different types of Serious Adverse Events o In five human clinical studies, PRTX - 100 has not had one drug related Serious Adverse Event - a Black Box Event. o To date, PRTX - 100 has shown a superior s
Slide 7: Efficacy of RA Drugs
Efficacy of RA Drugs 50% 50% 39% 0% 10% 20% 30% 40% 50% 60% Day 85 Day 113 Day 102 PRTX Enbrel MTX ACR50 Scores 0% 10% 20% 30% 40% 50% 60% 7 DAS28 < 3.2 Protalex, Inc .
Slide 8: Durability of Treatment
Protalex, Inc. Durability of Treatment Number of Treatments per Year 0 20 40 60 80 100 120 8 Number of Treatments per Year
Slide 9: What Drug Should be Used? The Answer is not Easy
What Drug Should be Used ? The Answer is not Easy To the left is EULAR’s summary of a 20 page recommendation for the treatment path of RA An RA drug would become the first choice to use - - If it was a safer treatment than the current drugs or If a Responder Screening Test for the drug exist
Slide 10: Competitive Advantages to Current Biologicals
Competitive Advantages of PRTX - 100 to Current Biologicals No FDA Black Box - Does not suppress the immune system Attractive safety profile allows for potential use in combination with other therapies Potentially applicable across a broad range of autoimmune diseases Considerably lower cost
Slide 11: Immune Thrombocytopenia (ITP): A Rare and Serious Disorder
Protalex, Inc. Immune Thrombocytopenia (ITP) A Rare and Serious Disorder An Orphan Disease in the US and Europe Abnormally low platelet count in the blood Daily or Weekly treatment for life Annual cost of treatment is about $60,000 Promacta® & Nplate® only globally approved treatments ($1B
Slide 12: Protalex Milestones
Protalex, Inc. Protalex Milestones x 2Q13 Safety data from first three cohorts of PRTX - 100 - 104 x 3Q13 Initiation of Cohort 5 extension study, to investigate monthly maintenance doses x 2Q14 Top - line results of PRTX - 100 - 104 trial x 4Q14 Filing IND for PRTX - 100 in ITP □ 1Q15 Top - line res
Slide 13: Development Plans
PRTX - 100 Development Plans 13 2012 2013 2014 2015 2016 2017 PRTX - 100 Rheumatoid Arthritis PRTX - 100 Immune Thrombocytopenia Phase 1 So. Africa PRTX - 100 - 103 Phase 1 in USA PRTX - 100 - 104 Phase 2 Phase 3 Explore Partnership Preclinical Phase 1/2 Phase 3 Protalex, Inc. 105 Continuation Study
Slide 14: Protalex Key Team Members
Protalex, Inc. Protalex Key Team Members Arnold P Kling – President, Director; Principal of Niobe Ventures, LLC, experienced investor in and manager of early stage technology companies James W Dowe III – Vice - Chair of SAB; active investor in biotechnology, computer software and investment mana
Slide 15: Patents and Intellectual Property
Protalex, Inc. Patents and Intellectual Property Patents (five issued in US and two in Japan) ▪ Initial US patent 7,211,258, “Protein A compositions and methods of use” filed 2002 and issued 2007 for RA, juvenile RA, and systemic lupus erythematosus ▪ Continuation patents expanding use were issued
Slide 16: Protalex Investment Thesis Summary
Protalex, Inc. Protalex Investment Thesis Summary PRTX - 100 – potentially a blockbuster drug ▪ Potential treatment of diseases in both large and small markets (RA, ITP) ▪ Potentially efficacy in a number of orphan diseases ▪ Considerable cost of goods advantage over competitive drugs ▪ To date, a
Slide 17: Protalex PRTX January 2015
PRTX PROTALE January, 2015